The European Medicines Agency has recommended against EU marketing approval for Ipique (bevacizumab), which would have been the first drug containing the antibody to be authorized for use in neovascular (wet) age-related macular degeneration (AMD).
The EMA today announced that its human drugs committee, the CHMP, issued a negative opinion on the product on 11 November during its monthly meeting